{"url_path":"/sec/revb/8-k/2026-06-24/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-281200-index.html","accession_number":"0001193125-26-281200","cik":"0001810560","ticker":"REVB","issuer_name":"REVELATION BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-281200-index.html","primary_entity_key":"0001810560","primary_entity_name":"REVELATION BIOSCIENCES, INC."},"word_count":382,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n \n\nOn June 24, 2026, Revelation Biosciences, Inc. (the “Company”) entered into an Amended and Restated Executive Employment Agreement with each of James Rolke, the Company’s Chief Executive Officer (“CEO”), and Chester S. Zygmont, III, the Company’s Chief Financial Officer (“CFO”), in each case effective as of June 24, 2026 (collectively, the “Amended Employment Agreements”). The Amended Employment Agreements reflect the following material changes:\n\n \n\n•\nAn increase in the change in control severance benefits to be received by each of the CEO and CFO in the event he experiences a “covered termination” (as defined in the Amended Employment Agreement) during the period beginning three months prior to a “change in control” (as defined in the Amended Employment Agreement) and ending 12 months after a change in control, including specifically: (i) a severance base amount equal to 2x the sum of: (a) his current base salary and (b) target annual bonus; (ii) a pro rata portion of his target annual bonus for the year in which the CEO or CFO is terminated; (iii) reimbursement of up to 18 months of premiums under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended;\n\n \n\n•\nIncreased flexibility for the CEO or CFO to engage in certain other activities outside the scope of his employment with the Company so long as such other activities are deemed beneficial to the Company or at least not detrimental, as determined by an independent committee of the Company’s Board of Directors; and\n\n \n\n•\nAn initial term of three years commencing on June 24, 2026 and automatic renewal terms for successive one-year periods thereafter unless either party provides at least 30 days’ prior written notice of non-renewal.\n\n \n\nThe Amended Employment Agreements also contain certain immaterial changes intended to conform language to the foregoing changes, document the CEO’s and CFO’s current base salaries and target bonus percentages, and provide additional clarification.\n\n \n\nThe foregoing description of the Amended Employment Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of each Amended Employment Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference."}